
Oseltamivir (Tamiflu) Facts:
- Antiviral drug that slows the spread of influenza virus between cells in the body.
- It stops newly produced virus from chemically cutting (neuraminidase inhibitor) ties with its host cell.
- Early treatment is important as neuraminidase protein inhibition is more effective within the first 48 hours.
- Worldwide, from October 2009, only 39 of > 10,000 samples of 2009 pandemic H1N1 swine flu have shown resistance to Oseltamivir.
- Prevention & treatment of influenzavirus A & influenzavirus B infection.
- Oseltamivir is approved for use in persons age 1 year & over.
- The usual adult dosage, for active infection, is 75 mg twice daily for 5 days.
- The treatment should begin within 2 days of the appearance of flu symptoms.
- Reduced doses are needed for children & people with kidney impairment.
- Can be given as a preventive, i.e. community outbreak or close contact with flu case.
- The prophylaxis dose is 75 mg once daily (people aged 13 years & older), safe & effective for up to 6 weeks.
- Taken orally as a pro-drug which becomes active after passing through the liver.
- Common adverse drug reactions (ADRs) (occurring in >1% of trial participants) include:
- Abdominal pain
- Diarrhea,
- Headache
- Nausea
- Vomiting
- Rare ADRs include:
- Anaphylaxis
- Hepatitis & elevated liver enzymes
- Rash
- Stevens-Johnson syndrome
- Sold under the trade name Tamiflu.
- Developed by C.U. Kim, W. Lew and X. Chen of US based Gilead Sciences (hold patent until 2016).
- Marketed worldwide by the pharmaceutical company Hoffmann–La Roche (Roche).
- Marketed by Chugai Pharmaceutical Co., in Japan, which is > 50% owned by Roche.
- First orally active neuraminidase inhibitor commercially developed.
Posted by ALCHEssMIST.
Alchemipedia | Home | Index | AZ | Numbers | Years | Animals | Architecture | Art | Business | Fashion | Films | Food & Drink | Games | Health | History | Literature | Media | Music | People |Politics | Science | Sport | Technology | World |
No comments:
Post a comment